Jan Van den Berghe
Co-Founder @ Novalis Biotechnology Incubation
Cranbrook, Canada
Jan Van den Berghe is a seed investor at Novalis Biotechnology Incubation in Cranbrook focused on Biotechnology and Genetics. Jan Van den Berghe is based out of Cranbrook, England and is the Co-Founder of Novalis_Fund. Jan previously worked at OHMX.bio as a Director. Jan Van den Berghe attended INSEAD.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Jan Van den Berghe invests in
Stages Jan Van den Berghe invests in
Countries Jan Van den Berghe invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (67%)
- Genetics 1 (33%)
- Biopharma 1 (33%)
- Therapeutics 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
Country
- France 1 (33%)
- Switzerland 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Alithea Genomics develops molecular biology tools and sequencing-based solutions for large-scale gene expression analysis. The company provides technologies that use RNA barcoding and multiplexing methods to enable the analysis of many RNA samples within a single sequencing experiment. Its products support workflows for RNA sequencing, includinglibrary preparation methods designed for transcriptome profiling and gene expression studies. Alithea Genomics also offers reagents, protocols, and software tools that assist researchers in processing sequencing data and interpreting gene expression results. These technologies are used in academic and industry research settings to study biological processes, disease mechanisms, and cellular responses through transcriptomic analysis. | $3.8M / Seed / Mar 04, 2026 | ||
| Alithea Genomics develops molecular biology tools and sequencing-based solutions for large-scale gene expression analysis. The company provides technologies that use RNA barcoding and multiplexing methods to enable the analysis of many RNA samples within a single sequencing experiment. Its products support workflows for RNA sequencing, includinglibrary preparation methods designed for transcriptome profiling and gene expression studies. Alithea Genomics also offers reagents, protocols, and software tools that assist researchers in processing sequencing data and interpreting gene expression results. These technologies are used in academic and industry research settings to study biological processes, disease mechanisms, and cellular responses through transcriptomic analysis. | $3.2M / Seed / Mar 14, 2024 | ||
| Carroucell is the microcarrier supplier for cell culture in bioreactor. | $1.5M / Series A / Sep 07, 2022 |
Co-Investors
Novalis Biotech Incubation seeds biotechnology and life sciences-related companies. We focus on early-stage start-ups and support their evolution by providing funding, sharing our professional and academic connections, and help to shape the business strategy in order to create value for all stakeholders.
Novalis Biotechnology Incubation Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jan Berghe
Managing Director & Co-Founder
|
|||
|
Jan Van den Berghe
Co-Founder
|
|||
Kjell Mortier
Fund Manager
|
|||
Wim van Criekinge
Co-Founder & Managing Director
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Jan Van den Berghe invest in?
Jan Van den Berghe invests primarily in Biotechnology, Genetics and Biopharma startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jan Van den Berghe?
Public channels for Jan Van den Berghe include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jan Van den Berghe last invest?
The most recent investment recorded for Jan Van den Berghe closed in Mar 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
